Literature DB >> 1416421

Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation.

K J Killian1, P Leblanc, D H Martin, E Summers, N L Jones, E J Campbell.   

Abstract

Dyspnea, leg effort (Borg 0 to 10 scale), ventilation, and heart rate (VEmax/VEcap; HRmax/HRcap expressed as a percentage of capacity) were measured at maximal exercise (cycle ergometer) in 97 patients with chronic airflow limitation (CAL) (FEV, 46.6 +/- 14.23% of predicted) and compared with 320 matched control subjects. Patients with CAL achieved a maximum power output of 86 +/- 39.5 W (60 +/- 23.2% of predicted) compared with 140 +/- 37.5 W (98 +/- 14.5% of predicted) in controls (p less than 0.0001), VEmax/VEcap was 72 +/- 19.3% compared with 53 +/- 18.6% (p less than 0.0001), and HRmax/HRcap was 76 +/- 13.5% compared with 82 +/- 13% (p less than 0.001). These findings were expected. The median intensity of dyspnea was 6 (severe to very severe) and leg effort was 7 (very severe) in both groups, and these findings were unexpected. The patients with CAL were handicapped by an increase in both dyspnea and peripheral muscular effort relative to the actual power output. The rating of dyspnea exceeded leg effort in 25 (26%) of CAL versus 69 (22%) control subjects: the rating of leg effort exceeded dyspnea in 42 (43%) CAL and 117 (36%) control subjects; both were rated equally in 30 (31%) CAL and 134 (42%) control subjects, respectively (NS). VEmax/VEcap and HRmax/HRcap were not significantly different in those limited by dyspnea, leg fatigue, or a combination of both. All values are expressed +/- SD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416421     DOI: 10.1164/ajrccm/146.4.935

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  67 in total

Review 1.  Enhancing physical performance in chronic obstructive pulmonary disease.

Authors:  M C Steiner; M D Morgan
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

2.  Impaired adrenergic- and corticotropic-axis outflow during exercise in chronic obstructive pulmonary disease.

Authors:  Ali Iranmanesh; Dudley F Rochester; Jing Liu; Johannes D Veldhuis
Journal:  Metabolism       Date:  2011-05-31       Impact factor: 8.694

3.  Moran Campbell and clinical science.

Authors:  G J Gibson
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

4.  Assessing the exercise response to a bronchodilator in COPD: time to get off your bike?

Authors:  M D L Morgan; S J Singh
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

5.  Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.

Authors:  A Ikeda; K Nishimura; H Koyama; M Tsukino; M Mishima; T Izumi
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

6.  Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia.

Authors:  A A Okubadejo; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

7.  Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension.

Authors:  G Valli; C D Vizza; P Onorati; R Badagliacca; R Ciuffa; R Poscia; F Brandimarte; F Fedele; P Serra; P Palange
Journal:  Eur J Appl Physiol       Date:  2007-11-03       Impact factor: 3.078

8.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

9.  Effects of inspiratory muscle warm-up on locomotor muscle oxygenation in elite speed skaters during 3000 m time trials.

Authors:  Philippe Richard; François Billaut
Journal:  Eur J Appl Physiol       Date:  2018-10-22       Impact factor: 3.078

Review 10.  [Heart and lungs : cardinal symptom dyspnea].

Authors:  M O Henke; C F Vogelmeier
Journal:  Herz       Date:  2013-05       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.